Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes
2 minutes ago - PR Newswire via Dow Jones News
-- Patients treated with ITCA 650 for 6 months showed an average HbA1c reduction of -3.2% at the time of the interim analysis; patients at baseline had HbA1c greater than or equal to 10% to 12%.